BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17805035)

  • 1. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience.
    Lethaby C; Wiernikowski J; Sala A; Naronha M; Webber C; Barr RD
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):613-6. PubMed ID: 17805035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
    Wiernikowski JT; Barr RD; Webber C; Guo CY; Wright M; Atkinson SA
    J Oncol Pharm Pract; 2005 Jun; 11(2):51-6. PubMed ID: 16460605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment.
    Rudge S; Hailwood S; Horne A; Lucas J; Wu F; Cundy T
    Rheumatology (Oxford); 2005 Jun; 44(6):813-8. PubMed ID: 15695300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of bone metabolism in children with acute lymphoblastic leukemia after induction chemotherapy treatment.
    Athanassiadou F; Tragiannidis A; Rousso I; Katsos G; Sidi V; Koliouskas D; Papastergiou C; Tsituridis I
    Pediatr Hematol Oncol; 2005 Jun; 22(4):285-9. PubMed ID: 16020115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate treatment in osteogenesis imperfecta.
    Madenci E; Yilmaz K; Yilmaz M; Coskun Y
    J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
    Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
    Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
    Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
    Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
    Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
    Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of osteoporosis/osteopenia in pediatric leukemia and lymphoma.
    Bryant ML; Worthington MA; Parsons K
    Ann Pharmacother; 2009 Apr; 43(4):714-20. PubMed ID: 19336653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Alendronate to Treat Osteopenia in Children During Therapy for Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of Sequential Outcomes.
    MacDonald P; Cranston A; Virdee M; Farncombe T; Athale U; Barr RD
    J Pediatr Hematol Oncol; 2023 May; 45(4):200-206. PubMed ID: 36729669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone and mineral abnormalities in childhood acute lymphoblastic leukemia: influence of disease, drugs and nutrition.
    Atkinson SA; Halton JM; Bradley C; Wu B; Barr RD
    Int J Cancer Suppl; 1998; 11():35-9. PubMed ID: 9876475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
    Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of bone mineral density and risk factors in children completing treatment for acute lymphoblastic leukemia.
    Gunes AM; Can E; Saglam H; Ilçöl YO; Baytan B
    J Pediatr Hematol Oncol; 2010 Apr; 32(3):e102-7. PubMed ID: 20216235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.